BioVie, an early stage biotech developing therapies for cirrhosis, postponed its IPO on Monday. It had filed to raise $15 million by offering 1.3 million shares based on a price of $11.44, the as-converted last close of its shares on the OTC (BIVI).
The Los Angeles, CA-based company was founded in 2013 and had planned to list on the Nasdaq under the symbol BIVI. ThinkEquity was set to be the sole bookrunner on the deal.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.